4565 (4565) News
Follow 4565 (4565) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Nxera Pharma Licenses Lucerastat Rights in APAC for CHF 7M Upfront
Nxera exercised its option to license lucerastat from Idorsia, securing exclusive rights in Japan, South Korea, Taiwan and select APAC markets outside China. It will pay CHF 7 million upfront and contribute to the global
EQUITY | Oct 28, 2026, 07:34 AM UTC
L
Nxera Pharma to receive $8.6 million milestone from Centessa
Nxera Pharma Co., Ltd. will receive a $8.6 million milestone payment from Centessa Pharmaceuticals following late-stage development progress.
EQUITY | Sep 03, 2026, 06:32 AM UTC
M
NBIX gets FDA IND acceptance for NBI-1117567 Phase 2 Alzheimer’s cognition
Neurocrine Biosciences, Nxera Pharma’s partner, received FDA IND acceptance for a Phase 2 study of NBI-1117567 targeting Alzheimer’s cognition.
EQUITY | Aug 26, 2026, 07:37 AM UTC